Recent studies spearheaded by Rotinen et al. [5] and Guo et al. [6] showed that ONECUT2 is an important regulator of AR-mediated growth and a driver of NE differentiation in transition from adenocarcinoma to NEPC, and is being investigated as a new drug target with potential therapeutic implications. Here, AR is linked to adenocarcinoma.